Search

ABT-510

ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. … It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

PG-530742

Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

N-(3-carboxypropanoyl)-L-norvaline

These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom. … N-(3-carboxypropanoyl)-L-norvaline is a solid. This compound belongs to the n-acyl-alpha amino acids.

NV-18

NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. … phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer of

Technetium Tc-99m ciprofloxacin

99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis

Befunolol

Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

ATX-101

Deoxycholic acid is a naturally occurring bile acid produced by the liver as one of several end products of cholesterol metabolism. … As a naturally occurring component of the human body, deoxycholate is considered a ‘biocompatible’ detergent that solubilizes fat in the small intestine.

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Alfaxalone

Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. … Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.

Tifuvirtide

Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.